GW Pharmaceuticals PLC (NASDAQ:GWPH)

161.10
Delayed Data
As of May 25
 +1.14 / +0.71%
Today’s Change
92.65
Today|||52-Week Range
161.82
+22.04%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$4.0B

Company Description

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.

Contact Information

GW Pharmaceuticals Plc
Sovereign House
Cambridge Cambridgeshire CB24 9BZ
P:441223266800
Investor Relations:
(917) 280-2424

Employees

Shareholders

Mutual fund holders47.07%
Other institutional41.17%
Individual stakeholders--

Top Executives

Justin D. GoverChief Executive Officer & Executive Director
Christopher John ToveyChief Operating Officer
Scott M. GiacobelloChief Financial Officer
Volker KnappertzChief Medical Officer
Julian S. GangolliPresident-North American Region